IBD | Jotup

Surrozen Provides Corporate Update on Clinical Programs

Retrieved on:

Thursday, January 18, 2024

Patient, Chronic liver disease, Tissue, IBD, Inflammatory bowel disease, Safety, Crosstalk (biology), Therapy, Regeneration, Boehringer Ingelheim, Clinical trial, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that enrollment for the SZN-043 Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers is complete. The Company expects to release safety and pharmacodynamic data in Q1 2024. In addition, Surrozen anticipates initiating enrollment in the Phase 1b portion of the study in patients with alcohol-associated hepatitis soon with proof-of-concept data from the study potentially available in the second half of 2024.

Key Points:

In addition, Surrozen anticipates initiating enrollment in the Phase 1b portion of the study in patients with alcohol-associated hepatitis soon with proof-of-concept data from the study potentially available in the second half of 2024.
Following the completion of the Phase 1 single ascending dose clinical trial for SZN-1326, the Company will discontinue development of SZN-1326 in inflammatory bowel disease (IBD).
The decision was based on the challenges of identifying a safe and potentially effective dose along with strategic considerations including the significant clinical development expenses and market competition in IBD.
SZN-1326 has been evaluated in a Phase 1 single ascending dose clinical trial in 37 healthy volunteers in doses ranging from 0.01mg to 25mg.

Antares Taps Jack Snyder to Spearhead Firm’s Private Wealth Strategy

Retrieved on:

Wednesday, January 24, 2024

Asset Management, Professional Services, Finance, Investment, Capital, Asset management, Nuveen, RIA, IBD, Private banking, Antares, Cryptocurrency

Antares Capital (“Antares”), a leading alternative asset manager with $67B+ in capital under management and administration, today announced that Jack Snyder has joined the firm as Managing Director, Head of U.S.

Key Points:

Antares Capital (“Antares”), a leading alternative asset manager with $67B+ in capital under management and administration, today announced that Jack Snyder has joined the firm as Managing Director, Head of U.S.
In this newly created role, Mr. Snyder will oversee the launch of Antares’ private wealth strategy, where he will play an integral role in increasing the firm’s assets under management through the development of strategic relationships in the wealth channel.
“Private wealth is an important driver of our growth strategy, and Jack’s addition will be critical in meeting the demand for alternative credit solutions in the private wealth channel.”
Mr. Snyder has a proven track record in alternatives distribution and robust experience in the Wirehouse, IBD, RIA and Private Bank channels.
“The U.S. wealth channel represents a vast market opportunity for alternative credit, which is why I’m excited to join Antares and build out their wealth platform,” said Mr. Snyder.

Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001

Retrieved on:

Tuesday, January 23, 2024

Dr. Olson joins Enthera’s management team with over two decades of leadership experience in the biopharmaceutical industry including a successful career at AbbVie.

Key Points:

Dr. Olson joins Enthera’s management team with over two decades of leadership experience in the biopharmaceutical industry including a successful career at AbbVie.
“We are entering the new year with positive momentum in Enthera’s corporate and clinical evolution with Lisa’s appointment as CEO and important progress with Ent001.
We are thrilled to have her join as CEO,” said Silvano Spinelli, Chairman of the Enthera Board of Directors.
Based on this, Enthera has initiated a multiple ascending dose (MAD) Phase 1b clinical trial in patients with moderately to severely active UC.

Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)

Retrieved on:

Wednesday, January 17, 2024

Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading physicians in inflammatory bowel disease (IBD) who will provide strategic input based on their deep scientific knowledge and clinical expertise.

Key Points:

Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading physicians in inflammatory bowel disease (IBD) who will provide strategic input based on their deep scientific knowledge and clinical expertise.
Together, they will guide Geneoscopy through the development of their RNA-based technology to assess stool samples for epithelial and immunological markers that may predict individual response to IBD therapeutics and improve monitoring of disease activity.
“Establishing a Scientific Advisory Board focused on IBD is a significant step forward in our mission to transform GI health,” said Erica Barnell, MD, PhD, Chief Medical and Scientific Officer of Geneoscopy.
“It is an honor to have such distinguished advisors to help us identify significant opportunities to advance methods for IBD diagnostics using our innovative RNA technology.

Pragma Bio and DayTwo Join Forces to Illuminate the Path to IBD Disease Management

Retrieved on:

Wednesday, January 17, 2024

Pragma Bio believes that those phenotypically correlated biosynthetic pathways are the hidden path to predict and make novel clinical biomarkers and small molecules to change the landscape of IBD disease management.

Key Points:

Pragma Bio believes that those phenotypically correlated biosynthetic pathways are the hidden path to predict and make novel clinical biomarkers and small molecules to change the landscape of IBD disease management.
Pragma Bio and DayTwo aim to identify biosynthetic pathways associated with IBD.
This approach overcomes many existing hurdles of drug design and optimizes for both safety and significantly improved management of disease.
By harnessing cutting-edge technology and comprehensive datasets, Pragma Bio and DayTwo will make groundbreaking contributions to the field of IBD research and therapeutics,” said Aamir Rehman, CEO of DayTwo.

New Study Shows SonarMD Drives 10X Reduction in Hospital Admissions and Emergency Visits Related to IBD

Retrieved on:

Friday, January 26, 2024

Patient, Research, LAS, MD, Importance, Health, IBD, Inflammatory bowel disease, ED, Bias, Inflammatory Bowel Diseases, Risk, Burrill Bernard Crohn, Therapy, Population health, Abstract, Physician, Nursing

CHICAGO and LAS VEGAS, Jan. 25, 2024 /PRNewswire/ -- Technology-enabled patient engagement leads to 10 times fewer hospital admissions and emergency department (ED) visits among patients with inflammatory bowel disease (IBD), according to new research presented at the seventh annual Crohn's & Colitis Congress®, a meeting convening the IBD experts to transform patient care. This finding underscores the importance of proactive patient engagement as the foundation for population health.

Key Points:

The study examined claims data of over 1,000 patients with IBD between January 2022 and December 2022.
Eighty percent (939 patients) were enrolled in SonarMD's program and 20% (234 risk-matched patients) were not enrolled during the study period.
Researchers measured disease-related ED visits, inpatient hospital admissions and the use of therapeutics, including biologics.
SonarMD helps practices overcome the first challenge of managing patients with complex chronic disease — engagement," said Beth Houck, CEO of SonarMD.

EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies

Retrieved on:

Saturday, January 13, 2024

Senior, Translation, Patient, Frankfurt Stock Exchange, Therapy, Research, MDAX, EVO, IBD, Inflammatory bowel disease, Drug discovery, Fibrosis, Doctor of Philosophy, Ulcerative colitis, Pharmaceutical industry

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has joined forces with the Crohn’s & Colitis Foundation (“the Foundation”), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease (“IBD”), which includes Crohn’s disease and ulcerative colitis.

Key Points:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has joined forces with the Crohn’s & Colitis Foundation (“the Foundation”), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease (“IBD”), which includes Crohn’s disease and ulcerative colitis.
Under the collaboration, Evotec joins forces with the Foundation’s IBD Therapeutics Incubator programme that facilitates collaboration between the Foundation, academic researchers, and industry partners to translate groundbreaking basic research that was performed by academic researchers and identified by the Foundation into medical innovations for IBD patients.
“We’re actually driving research from idea to therapeutic product opportunity.”
“We’re excited to initiate these drug discovery projects with top-notch academic investigators and the experienced scientists at Evotec,” said Jennifer Swantek, PhD, Director of the Foundation’s IBD Therapeutics Incubator programme.
“We’re eager to deliver much needed, differentiated therapies to Crohn’s disease and ulcerative colitis patients as soon as possible.”
No financial terms of the collaboration were disclosed.

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

Retrieved on:

Tuesday, January 9, 2024

Biology, Fibrosis, Organovo, UC, SAN, Partnership, Tissue, IBD, Inflammatory bowel disease, Executive, Cirrhosis, Research and development, Disease, 3D, NASH, Colitis, Ulcerative colitis, FXR, Ulcer

The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.

Key Points:

The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.
“We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo's Executive Chairman.
Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025.
The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.

Arkadios Capital Marks Growth and Success in 2023, Eyes Continued Expansion in 2024

Retrieved on:

Wednesday, January 10, 2024

RIA, IBD, ACG, Atlanta Business Chronicle, ELITE, Executive director, Business consultant, Strategic management, Growth, Financial adviser

ATLANTA, Jan. 10, 2024 /PRNewswire/ -- Arkadios Capital, a leading hybrid broker-dealer, marks another year of remarkable growth, adding 15 advisory groups and nearly $3 billion in new assets to their platform.

Key Points:

ATLANTA, Jan. 10, 2024 /PRNewswire/ -- Arkadios Capital, a leading hybrid broker-dealer, marks another year of remarkable growth, adding 15 advisory groups and nearly $3 billion in new assets to their platform.
"As we enter 2024, Arkadios remains dedicated to providing larger teams and advisors with an elite platform to power their business and better serve clients," said Founder and CEO David Millican.
For the second consecutive year, Arkadios Capital earned a coveted spot on the prestigious Association of Corporate Growth (ACG) Georgia Chapter Fast 40 list, a testament to the company's sustained growth and success.
Arkadios Capital anticipates building on this momentum in 2024, fostering continued growth, innovation and unparalleled support for its advisors.

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024

Retrieved on:

Thursday, January 4, 2024

IBD, Food, Economics, Artificial intelligence, Letter, FDA, Cystic fibrosis, Gastrointestinal disease, Stanford University, Gastroparesis, Niclosamide, BOCA, Steatorrhea, Growth, Investment, First wave, Patient, Pharmaceutical industry

BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, has issued a Letter to Stockholders highlighting the Company’s recent accomplishments and plans for 2024.

Key Points:

BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, has issued a Letter to Stockholders highlighting the Company’s recent accomplishments and plans for 2024.
The close of 2023 has been an exciting period for First Wave BioPharma, highlighted by the recently announced potential business combination with ImmunogenX.
The non-binding term sheet includes a low seven-figure payment to First Wave BioPharma along with economics related to future milestones and royalties.
2024 has the potential to be a year of significant growth for First Wave BioPharma, and once again, I thank all of our stockholders for your continued support.